ライフサイエンスコーパス: EMD

1 EMD + NBM-treated defects showed a mean CAL change from

2 EMD 57033-binding protects myosin against heat stress an

3 EMD also enhanced (by 20% to 40%) the expression of tran

4 EMD and P2 promoted reepithelialization and neovasculari

5 EMD and P2 significantly promoted early wound closure at

6 EMD exhibited strong cytotoxicity toward various human l

7 EMD gel adsorbed less protein to the surface of grafting

8 EMD had an effect on levels of cytokines related to fibr

9 EMD had no effect on the epithelial gap of the wound.

10 EMD improves oral mucosa incisional wound healing by pro

11 EMD induced a concentration-dependent increase of CTGF p

12 EMD induced dramatic c-Myc degradation through a ubiquit

13 EMD maintained a significant acceleration of reepithelia

14 EMD may provide greater DF compared to non-treated contr

15 EMD may provide greater DF under diabetic or normal cond

16 EMD or TGF-beta1 provoked a significant increase of IL-1

17 EMD provided an increased defect fill (DF) in G1 and hig

18 EMD provided an increased DF in both groups and enhanced

19 EMD provides highest levels of CRC; however, the additio

20 EMD significantly increased cell proliferation at 3 and

21 EMD significantly increased PMN chemotactic activity (P

22 EMD stimulates CTGF expression in human PDL cells, a pro

23 EMD therapy of intrabony defects promotes additional ben

24 EMD treatment predictably alters a dysbiotic subgingival

25 EMD+CAF continues to show histologic evidence of periodo

26 EMD- and TGF-beta1-stimulated CTGF expression was signif

27 On both days 5 and 9, EMD treatment increased significantly the number of bloo

28 CTGF can affect EMD- and TGF-beta1-induced PDL cell proliferation, but i

29 Mutations in LMNA encoding lamin A/C and EMD encoding emerin cause cardiomyopathy and muscular dy

30 differences among control, blood-coated, and EMD-coated DFDBA particles.

31 The effect of CTGF and EMD on osteoblastic mRNA expression in PDL cells is not

32 SCTGs, matrix grafts, and EMD were superior to CAF in achieving CRC, but SCTGs sho

33 Merck Serono (Merck KGaA) and EMD Serono (Merck KGaA).

34 that the combination of EMD liquid + NBM and EMD liquid + DFDBA adsorbed higher amounts of amelogenin

35 0.63 +/- 0.42 mm) compared with the OFD and EMD groups (P <0.05).

36 -resolution immunocytochemistry with an anti-EMD antibody.

37 munostaining assay with gold-conjugated anti-EMD antibody.

38 In univariable analysis, the presence of any EMD ( P = .005), skin involvement ( P = .002), spleen (

39 This investigation compares applying EMD in solution to cells with precoating of wells with E

40 ur, which was similar to adjacent tissues at EMD-treated sites but greater than adjacent tissues at a

41 non-contained defects may be limited because EMD does not maintain a space itself.

42 tatistically significant differences between EMD + CAF and CTG + CAF for any measured parameter.

43 the frequency of residual PD >/=6 mm between EMD + DBBM (5%) and CM + DBBM (15%) (P = 0.21).

44 ng the frequency of CAL gain >/=4 mm between EMD + DBBM (60%) and CM + DBBM (50%) or comparing the fr

45 However, EMD and BONE+EMD groups demonstrated more long-term reductions in a h

46 CTGF inhibition downregulated both EMD- and TGF-beta1-induced DNA synthesis.

47 No cytotoxic effects caused by EMD were detected.

48 urthermore, amelogenin proteins delivered by EMD liquid were able to penetrate the porous surface str

49 pe evaluation, and acid etching, followed by EMD or saline application.

50 ver, the anti-inflammatory effect induced by EMD observed in the in vitro study could not be confirme

51 f the epithelial barrier function induced by EMD were investigated by analysis of transepithelial ele

52 n stimulation was significantly inhibited by EMD (P <0.05).

53 atrial natriuretic peptide is suppressed by EMD 57033.

54 Wounds treated by EMD and P2 showed increased angiogenesis during the firs

55 with CAF (n = 17), CAF + CM (n = 17), CAF + EMD (n = 17), and CAF + CM + EMD (n = 17).

56 ither CAF (n = 17); CAF + CM (n = 17); CAF + EMD (n = 17), or CAF + CM + EMD (n = 17).

57 superior length of NC [4.13 +/- 1.22 (CAF + EMD); 3.95 +/- 1.11 (CAF + CM + EMD); 2.94 +/- 0.77 (CAF

58 with the other groups [1.09 +/- 0.26 (CAF + EMD); 1.04 +/- 0.34 (CAF + CM); and 1.14 +/- 0.29 (CAF),

59 0.68 (CAF + CM + EMD); 3.01 +/- 0.56 (CAF + EMD); 2.15 +/- 0.47 (CAF + CM); 2.29 +/- 0.82 (CAF), P =

60 6 months was significant for CAF + CM, CAF + EMD, and CAF + CM + EMD (P <0.05).

61 tients with GRs treated with CAF + CM, CAF + EMD, and CAF + CM + EMD.

62 ronally advanced flap (CAF); CAF + CM; CAF + EMD; and CAF + CM + EMD (split-mouth design).

63 Complete root coverage (CRC) for CAF + EMD was 70.59%, significantly superior to CAF alone (23.

64 A small molecule called EMD 57033 can repair motor proteins that have stopped wo

65 early does not derive its input from classic EMDs.

66 (23.53%); CAF + CM (52.94%), and CAF + CM + EMD (51.47%) (P <0.05).

67 (n = 17); CAF + EMD (n = 17), or CAF + CM + EMD (n = 17).

68 (n = 17), CAF + EMD (n = 17), and CAF + CM + EMD (n = 17).

69 cant for CAF + CM, CAF + EMD, and CAF + CM + EMD (P <0.05).

70 p (CAF); CAF + CM; CAF + EMD; and CAF + CM + EMD (split-mouth design).

71 A superior STT was observed for CAF + CM + EMD group (1.5 +/- 0.33) when compared with the other gr

72 1.22 (CAF + EMD); 3.95 +/- 1.11 (CAF + CM + EMD); 2.94 +/- 0.77 (CAF + CM); 2.72 +/- 0.81 (CAF), P =

73 P = 0.02] and NB [3.21 +/- 0.68 (CAF + CM + EMD); 3.01 +/- 0.56 (CAF + EMD); 2.15 +/- 0.47 (CAF + CM

74 ted with CAF + CM, CAF + EMD, and CAF + CM + EMD.

75 liquid carrier system for EMD, used to coat EMD, may be advantageous for better surface coating.

76 results of this study suggest that combining EMD and SPPF in the treatment of suprabony defects may l

77 Most common EMD interventions given were intravenous fluids 57 (21%)

78 ial than the commercially available complete EMD compound and that the mechanism of action, in part,

79 an those of the other pools and the complete EMD compound and was concentration dependent.

80 Six of these pools, along with the complete EMD unfractionated compound and positive and negative co

81 Conversely, EMD did not induce MMP-8 secretion from PMNs.

82 P+CS (conservative surgery) (n = 20); AgP+CS/EMD (n = 20); CP+CS/EMD (n = 20).

83 No difference was observed between AgP+CS/EMD and CP+CS/EMD groups (P > 0.05).

84 ups during follow-up (P <= 0.05), and AgP+CS/EMD presented a higher rCAL gain (2.4 +/- 1.0 mm) when c

85 urgery) (n = 20); AgP+CS/EMD (n = 20); CP+CS/EMD (n = 20).

86 ce was observed between AgP+CS/EMD and CP+CS/EMD groups (P > 0.05).

87 eeth were divided into two groups: test (CTG-EMD, 79 teeth) and control (CTG only, 77 teeth).

88 of young adults-the Eccentric Muscle Damage (EMD; n = 156) cohort and the Functional Single Nucleotid

89 Using empirical mode decomposition (EMD), which allows measurement of narrow-band changes in

90 G + CAF or between enamel matrix derivative (EMD) + CAF and SCTG + CAF.

91 cal application of enamel matrix derivative (EMD) added to papilla reflection/root preparation (PR/RP

92 Enamel matrix derivative (EMD) and collagen membranes (CMs) are simultaneously app

93 the combination of enamel matrix derivative (EMD) and natural bone mineral (NBM) with and without add

94 Enamel matrix derivative (EMD) and recombinant human platelet-derived growth facto

95 ue graft (CTG) and enamel matrix derivative (EMD) approaches provided superior initial REC reduction

96 effect of using an enamel matrix derivative (EMD) as an adjunct to non-surgical periodontal therapy (

97 are the effects of enamel matrix derivative (EMD) associated with a hydroxyapatite and beta-tricalciu

98 e effectiveness of enamel matrix derivative (EMD) associated with a simplified papilla preservation f

99 en matrix (CM) and enamel matrix derivative (EMD) characteristics, it is suggested that their combina

100 The enamel matrix derivative (EMD) contains hundreds of peptides in different levels o

101 matrix (CM) and/or enamel matrix derivative (EMD) for the treatment of dehiscence-type recession defe

102 The use of an enamel matrix derivative (EMD) has been shown to enhance periodontal regeneration

103 eriodontal therapy enamel matrix derivative (EMD) has been successfully used for tissue regeneration

104 Enamel matrix derivative (EMD) has been used in periodontal regenerative procedure

105 Although enamel matrix derivative (EMD) has been used to promote periodontal regeneration,

106 Although enamel matrix derivative (EMD) has demonstrated the ability to promote angiogenesi

107 matrix (CM) and/or enamel matrix derivative (EMD) in combination with a coronally advanced flap (CAF)

108 ix graft (ADMG) or enamel matrix derivative (EMD) in conjunction with a coronally advanced flap (CAF)

109 ) with and without enamel matrix derivative (EMD) in the treatment of multiple Class III-IV Miller pe

110 Enamel matrix derivative (EMD) is suggested to stimulate transforming growth facto

111 entered results of enamel matrix derivative (EMD) therapy in intrabony defects in aggressive periodon

112 Use of enamel matrix derivative (EMD) when dealing with non-contained defects may be limi

113 the association of enamel matrix derivative (EMD) with ABG in the management of intrabony defects (IB

114 regeneration (GTR)/enamel matrix derivative (EMD) with and without laser treatment, the WMD of PD was

115 t a combination of enamel matrix derivative (EMD) with demineralized freeze-dried bone allograft (DFD

116 on treatments with enamel matrix derivative (EMD), a commercial formulation of EMPs, suggest that it

117 uate the effect of enamel matrix derivative (EMD), tyrosine-rich amelogenin peptide (TRAP), and a syn

118 ed with an enamel matrix protein derivative (EMD) combined with either a natural bone mineral (NBM) o

119 ith either enamel matrix protein derivative (EMD) or collagen membrane (CM).

120 Enamel matrix derivatives (EMDs) have been used in periodontal regenerative procedu

121 Enamel matrix derivatives (EMDs) have demonstrated proof-of-principle that periodon

122 ubstrate for the elementary motion detector (EMD) [2].

123 , via so-called elementary motion detectors (EMDs).

124 particle electrophoretic mobility diameter (EMD) can be achieved via gas-phase electrophoresis.

125 estrous phases (estrus/metaestrus/diestrus (EMD)) froze more during extinction retrieval than those

126 Purpose Extramedullary disease (EMD) at diagnosis in patients with acute myeloid leukemi

127 (n = 40) an electronic medication dispenser (EMD).

128 10 years and between treatment groups (i.e., EMD versus CTG) at the same time points were examined.

129 andomly treated with a combination of either EMD + NBM or EMD + beta-TCP.

130 ent study, regenerative therapy using either EMD + DBBM or CM + DBBM yielded comparable clinical outc

131 one grafts after surface coating with either EMD (as a liquid formulation) or EMD (as a gel formulati

132 llow-up investigation, treatment with either EMD + CAF or CTG + CAF for Miller Class I and II GR defe

133 ndomly assigned to the treatment with either EMD + DBBM (test: n = 20) or CM + DBBM (control: n = 20)

134 urgery of deep intrabony defects with either EMD + NBM + PRP or EMD + NBM.

135 bony defect was randomly treated with either EMD + NBM + PRP or EMD + NBM.

136 ium phosphate (CaP), were coated with either EMD liquid or EMD gel.

137 bling (inefficient) spliceosome assembly for EMD intron 5.

138 f the defects amounted to 6.1 +/- 1.9 mm for EMD + DBBM and 6.0 +/- 1.9 mm for CM + DBBM sites (P = 0

139 he potential for a liquid carrier system for EMD, used to coat EMD, may be advantageous for better su

140 lonal antibody was loaded onto the Fractogel EMD SO3 (M) cation exchanger at either pH 5 or pH 4.

141 hich 15 (8%) underwent surgery directly from EMD.

142 phosphate/hydroxyapatite graft (BONE group), EMD+BONE, or EMD alone.

143 In GTR/EMD with and without laser treatment, the WMD of CAL gai

144 e WMD of PD was negligible; however, the GTR/EMD group showed better outcomes (P = 0.005) than the la

145 e Department of Muhimbili National Hospital (EMD-MNH) in Dar Es Salaam, Tanzania with non-traumatic a

146 However, EMD and BONE+EMD groups demonstrated more long-term redu

147 Altogether, we identified EMD as a novel potent compound targeting oncogenic c-Myc

148 11 clinical trials, were studied to identify EMD, as defined by physical examination, laboratory find

149 en freezing and IL-BLA circuit activation in EMD animals, and a negative correlation in PRO animals.

150 ntly higher in G1 when compared to G2 and in EMD-treated sites of both groups.

151 Leukocyte infiltration was decreased in EMD-treated wounds at day 1 (P = 0.03), and P2 and TRAP

152 tive osteoclasts was significantly higher in EMD-treated sites of G1.

153 inction retrieval in PRO and enhancing it in EMD.

154 ning of 5'SS-branchpoint length in our index EMD case subject defines 45-47 nt as the critical elonga

155 The results provide novel insights into EMD-CTGF interaction in PDL cells.

156 ertebrate visual cortex the output from many EMDs is pooled in neurons sensitive to wide-field optic

157 predicted and observed environmental means (EMD) ranged between -4.95 and 4.67 days.

158 Mechanistically, EMD eliminated c-Myc in the cells and initiated caspase-

159 N-bis (5-ethyl-2-hydroxybenzyl) methylamine (EMD), and present evidence demonstrating its effectivene

160 N-bis (5-ethyl-2-hydroxybenzyl) methylamine (EMD), in targeting c-Myc in several lung cancer cell lin

161 The small molecule EMD 57033 has been shown to stimulate the actomyosin ATP

162 ured in elementary motion-detecting neurons (EMDs).

163 Non-EMD motion processing may therefore serve an important f

164 The non-EMD driven flicker sensitivity leads to strong, nondirec

165 s, indicating the generality of the observed EMD effects.

166 The IC(50) of EMD against lung cancer cells was approximately 60 uM.

167 aim of this study is to test the ability of EMD to adsorb to the surface of DFDBA particles and dete

168 anticancer and c-Myc-targeted activities of EMD support its use in potential new approaches to treat

169 beta receptor I kinase-dependent activity of EMD and make it available for potential target cells.

170 Addition of EMD 57033 to heat-inactivated beta-cardiac myosin is fol

171 The addition of EMD to CTG results in improved root coverage outcomes an

172 The results suggest that the addition of EMD to DFDBA particles may influence periodontal regener

173 The addition of EMD to PR/RP does not significantly improve clinical or

174 d controversial results after application of EMD combined with different types of bone grafting mater

175 rect diagnosis, or no adequate assessment of EMD at baseline.

176 efects after treatment with a combination of EMD and biphasic calcium phosphate (BC) or EMD alone.

177 n assay demonstrated that the combination of EMD liquid + NBM and EMD liquid + DFDBA adsorbed higher

178 ith this information, selected components of EMD can now be formulated for optimal osteo- and angio-g

179 The cotreatment of EMD with the proteasome inhibitor MG132 reversed its c-M

180 e present study was to compare the effect of EMD and its fractions on the cytokine profiles from huma

181 DFDBA particles and determine the effect of EMD coating on downstream cellular pathways such as adhe

182 To explore the effects of EMD and TGF-beta1 on CTGF expression, cells were treated

183 This study explores the effects of EMD and TGF-beta1 on CTGF in periodontal ligament (PDL)

184 This study examines the in vivo effects of EMD on healing of an oral mucosa surgical wound in rats.

185 igate proliferative and cytotoxic effects of EMD on oral epithelial cells and their possible influenc

186 Effects of EMD on oral epithelial cells are of crucial importance i

187 Cytotoxic effects of EMD treatment were sampled by lactate dehydrogenase rele

188 c analysis was used to study the fraction of EMD proteins binding to collagen.

189 e the incidence and clinical implications of EMD.

190 The overall incidence of EMD was 23.7%.

191 lood demonstrated a consistent even layer of EMD adsorption to the root surface.

192 In the presence of EMD 57033, ATP hydrolysis, coupling between actin and nu

193 risk and WBC count, neither the presence of EMD nor the number of specific sites of EMD were indepen

194 tic factors, irrespective of the presence of EMD.

195 Most patients (65.3%) had only one site of EMD, 20.9% had two sites, 9.5% had three sites, and 3.4%

196 e of EMD nor the number of specific sites of EMD were independently prognostic.

197 , in certain clinical situations, the use of EMD alone may not be sufficient to prevent flap collapse

198 The adjunctive use of EMD also resulted in significantly reduced pain 14 days

199 The use of EMD in combination with a coronally advanced flap compar

200 The use of EMD in furcations will give more reduction in horizontal

201 The adjunct use of EMD with SRP resulted in significantly greater improveme

202 fferent quadrants, were each treated by OFD, EMD, or EMD + HA/beta-TCP in each defect.

203 in, in osteoblasts and PDL cells cultured on EMD-coated DFDBA particles at 3, 7, and 14 days.

204 OC, in osteoblasts and PDL cells cultured on EMD-coated NBM particles.

205 K11, one HEXB, three DBT, one HRPT1, and one EMD cases).

206 s provide the best outcomes, whereas ADMG or EMD in conjunction with CAF may be used as an alternativ

207 advanced flap (CAF) combined with CM and/or EMD.

208 >/=6 mm were randomly treated with EMD/BC or EMD alone.

209 f EMD and biphasic calcium phosphate (BC) or EMD alone.

210 roxyapatite graft (BONE group), EMD+BONE, or EMD alone.

211 quadrants, were each treated by OFD, EMD, or EMD + HA/beta-TCP in each defect.

212 with either EMD (as a liquid formulation) or EMD (as a gel formulation).

213 ciated with ABG (22 patients; test group) or EMD+ABG (control group) in each defect.

214 (CaP), were coated with either EMD liquid or EMD gel.

215 with regenerative surgery using EMD + NBM or EMD + beta-TCP can be maintained over a period of 10 yea

216 ed with a combination of either EMD + NBM or EMD + beta-TCP.

217 abony defects with either EMD + NBM + PRP or EMD + NBM.

218 domly treated with either EMD + NBM + PRP or EMD + NBM.

219 Furthermore, prelayering EMD induced an increase of TER of primary cells.

220 t protein pools from a commercially produced EMD were collected based on molecular weight.

221 PPF technique; 25 participants also received EMD (test group) and 25 patients underwent flap surgery

222 ler Class I and II GR, each patient received EMD+CAF for three teeth and CTG+CAF for one tooth for ro

223 Both PR/RP+ EMD and PR/RP+S resulted in significant improvements in

224 roximal PD were randomly allocated to (PR/RP+EMD; n = 24) and control (PR/RP+saline; n = 26) therapie

225 ses to pairwise correlations in Drosophila's EMD neurons, T4 and T5.

226 These results suggest EMD may enhance barrier function.

227 ness flaps were raised, and, after suturing, EMD was injected underneath the soft tissues on one side

228 atomical substrates for the two arms of a T5 EMD circuit; Tm1 and Tm2 provide a second.

229 It was demonstrated that EMD and pool 7 induced phospho-SMAD, osterix, and VEGF-A

230 onclusion This large study demonstrates that EMD at any site is common but is not an independent prog

231 e results of the present study indicate that EMD application, irrespective of the combination with CM

232 Cycloheximide chase assay revealed that EMD tended to shorten the half-life of c-Myc by approxim

233 Here, we show that EMD 57033 binds to an allosteric pocket in the myosin mo

234 The in vitro study showed that EMD and its high and low molecular weight fractions redu

235 In vitro studies showed that EMD stimulates various cellular effects, which could pot

236 We further verified that EMD strongly induced the ubiquitination of c-Myc and pro

237 The EMD is associated with high compliance, and there are al

238 The EMD, which was used for the 1-year study period, recorde

239 The EMD-treated groups showed a superior length of NC [4.13

240 Although the EMD has been the preferred model for more than 50 years,

241 d an RMSE of 18.1 days, a PC of 0.41 and the EMD ranged between -31.5 and 28.7 days.

242 ed an RMSE of 7.3 days, a PC of 0.93 and the EMD ranged between -6.4 and 4.1 days while the conventio

243 In the EMD + beta-TCP group three defects had lost 2 mm, wherea

244 82% (i.e., nine of 11) of the defects in the EMD + beta-TCP group.

245 4% (i.e., seven of 11) of the defects in the EMD + NBM group and in 82% (i.e., nine of 11) of the def

246 At 10 years two defects in the EMD + NBM group had lost 2 mm, whereas two other defects

247 In the EMD + NBM group, one defect lost 2 mm and four other def

248 Four sites in the EMD + PRP + NBM group lost 1 mm of the CAL gained at 1 y

249 BC group and 3.30 +/- 1.89 mm (48.7%) in the EMD group were achieved.

250 BC group and 2.65 +/- 2.18 mm (36.2%) in the EMD group were obtained.

251 s from baseline values, including wKT in the EMD group, which at 1 year was not significantly improve

252 Men in the EMD study with two copies of the protective allele showe

253 CAL gain of 2.38 +/- 2.17 mm (24.9%) in the EMD/BC group and 2.65 +/- 2.18 mm (36.2%) in the EMD gro

254 eductions of 3.14 +/- 1.95 mm (39.6%) in the EMD/BC group and 3.30 +/- 1.89 mm (48.7%) in the EMD gro

255 At 12 and 24 months after treatment, the EMD + HA/beta-TCP group showed significantly greater PD

256 th the soft tissues on one side, whereas the EMD vehicle was injected in the contralateral side.

257 increase and DBL gain in comparison with the EMD+ABG combination.

258 nd in vivo, the specific elements within the EMD compound responsible for these effects remain unknow

259 The pattern of neural responses in the EMDs was inconsistent with one classical model of motion

260 glycopeptide enrichment kit offered through EMD Millipore.

261 Thus, EMD 57033 displays a much wider spectrum of activities t

262 ) were found for SCTG + CAF when compared to EMD + CAF (MD: -1.06 mm), and SCTG + CAF when compared t

263 superior epithelial length when compared to EMD-treated groups after 3 months.

264 available collagen products were exposed to EMD or recombinant TGF-beta1, followed by vigorous washi

265 ricalcium phosphate (HA/beta-TCP) implant to EMD alone and to open-flap debridement (OFD) when surgic

266 n matrix to adsorb the activity intrinsic to EMD that provokes transforming growth factor (TGF)-beta

267 nts obtained with regenerative surgery using EMD + NBM or EMD + beta-TCP can be maintained over a per

268 lity of the gingival margin over time, while EMD, acellular dermal matrix, collagen matrix, and flap

269 Grafting materials coated with EMD gel adsorbed more frequently to the exterior of graf

270 Samples coated with EMD lacking blood demonstrated a consistent even layer o

271 osed, using a bone graft in combination with EMD to avoid collapse of the flap into the bony defect d

272 ment of non-contained infrabony defects with EMD, with or without BC, resulted in statistically signi

273 r and more sustained O(2)(-) generation with EMD.

274 nct of an HA/beta-TCP composite implant with EMD may improve the clinical and radiographic outcomes o

275 Precoating of inserts with EMD induced a significant increase of TER and barrier fu

276 root resorption and ankylosis was noted with EMD+CAF.

277 appear to improve the results obtained with EMD + NBM.

278 Treatment decisions for patients with EMD should be made on the basis of recognized AML progno

279 DFDBA particles were precoated with EMD or human blood and analyzed for protein adsorption p

280 ium or added to wells/inserts precoated with EMD.

281 cles were precoated in various settings with EMD or human blood and analyzed for protein adsorption p

282 Human PDL cells were stimulated with EMD.

283 The sites treated with EMD + beta-TCP showed a mean CAL change from 9.1 +/- 1.6

284 The mean CAL gain at sites treated with EMD + DBBM was not statistically significantly different

285 n 83% (10 of 12) of the defects treated with EMD + NBM + PRP and in 100% (all 12) of the defects trea

286 The sites treated with EMD + NBM + PRP demonstrated a mean CAL change from 10.5

287 The defects treated with EMD + NBM demonstrated a mean CAL change from 8.9 +/- 1.

288 in 100% (all 12) of the defects treated with EMD + NBM.

289 imary keratinocytes were either treated with EMD dissolved in culture medium or added to wells/insert

290 Seven of the nine teeth treated with EMD+CAF demonstrated varying degrees of periodontal rege

291 groups: non-treated control and treated with EMD.

292 oups: non-treated (control) and treated with EMD.

293 epth (PD) >/=6 mm were randomly treated with EMD/BC or EMD alone.

294 of periodontal defects after treatment with EMD under the influence of CS in the rat model.

295 of periodontal defects after treatment with EMD under the influence of DM.

296 periodontal microbiome after treatment with EMD using a deep-sequencing approach.

297 ution to cells with precoating of wells with EMD.

298 rated by precoating culture plate wells with EMD.

299 ar-weight protein pools (7 to 17 kDa) within EMD have greater osteoinductive potential than the comme

300 ling and root planing (SRP) with and without EMD in 51 patients presenting with moderate to severe pe